Calidi Biotherapeutics (NYSE:CLDI) Shares Set to Reverse Split on Monday, July 15th

Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) are scheduled to reverse split on Monday, July 15th. The 1-10 reverse split was announced on Monday, July 15th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, July 15th.

Calidi Biotherapeutics Price Performance

CLDI stock opened at $0.16 on Friday. Calidi Biotherapeutics has a 1 year low of $0.14 and a 1 year high of $13.79.

Calidi Biotherapeutics (NYSE:CLDI) last posted its earnings results on Tuesday, May 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.07. Research analysts predict that Calidi Biotherapeutics will post -0.37 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. LADENBURG THALM/SH SH assumed coverage on shares of Calidi Biotherapeutics in a research note on Thursday, June 27th. They set a “buy” rating and a $1.00 price objective on the stock. Robert W. Baird lowered their target price on Calidi Biotherapeutics from $4.50 to $2.00 and set an “outperform” rating on the stock in a report on Wednesday, May 15th. Finally, HC Wainwright lowered their target price on Calidi Biotherapeutics from $11.00 to $2.00 and set a “buy” rating on the stock in a report on Thursday, March 21st.

Hedge Funds Weigh In On Calidi Biotherapeutics

Institutional investors have recently bought and sold shares of the stock. Apollo Management Holdings L.P. purchased a new position in Calidi Biotherapeutics in the 1st quarter worth about $71,000. Magnetar Financial LLC purchased a new position in Calidi Biotherapeutics in the 1st quarter worth about $36,000. Evermay Wealth Management LLC purchased a new position in Calidi Biotherapeutics in the 1st quarter worth about $36,000. Finally, Spectrum Asset Management Inc. NB CA purchased a new position in Calidi Biotherapeutics in the 1st quarter worth about $94,000. Hedge funds and other institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer with a novel stem cell-based therapy. Calidi Biotherapeutics Inc, formerly known as First Light Acquisition Group, is based in SAN DIEGO.